Detalle de: Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
| Title | Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 |
| Abstract |
Countering TB prodrug resistance The arsenal of antibiotics for treating tuberculosis (TB) contains many prodrugs, such as ethionamide, which need activation by normal metabolism to release their toxic effects. Ethionamide is potentiated by small molecules. Blondiaux et al. screened for more potent analogs and identified a lead compound called SMARt-420. This small molecule inactivates a TetR-like repressor, EthR2, and boosts ethionamide activation. SMARt-420 successfully promoted clearance of multidrug-resistant strains of Mycobacterium tuberculosis from the lungs of mice. Science , this issue p. 1206 |
| Apa Reference | Blondiaux, N., Moune, M., Desroses, M., Frita, R., Flipo, M., Mathys, V., Soetaert, K., Kiass, M., Delorme, V., Djaout, K., Trebosc, V., Kemmer, C., Wintjens, R., Wohlkönig, A., Antoine, R., Huot, L., Hot, D., Coscolla, M., Feldmann, J., Gagneux, S., Locht, C., Brodin, P., Gitzinger, M., Déprez, B., Willand, N. & Baulard, A.R. (2017). Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. Science, 355(6330), 1206-1211. 10.1126/science.aag1006 |
| Doi | 10.1126/science.aag1006 |
| Publication Date | 17 Mar 2017 |
| Publication Type | Article |
| Researcher | Mireia Coscolla Devis |
| Ontology | Drug Discovery and design, Drug resistance |
| Research Groups | |
| Tools |